Autolus Therapeutics PLC (AUTL) Actualités

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist...

Autolus Therapeutics announces publication in Cancer Immunology Research

LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16...

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage...